RECRUITING CLINICAL TRIALS

Please contact our clinical research manager, Amy Ewald, MS, at (727) 323-0077

2104 Atmosphere Study and RGX-314-3101 Ascent Study– A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD

BP41670 Burgundy Study – A Two-Part, Phase I Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7250284 following Intravitreal Administration of Unmasked Multiple Ascending Doses and Sustained Delivery from the Port Delivery System in Patients with Neovascular Age-Related Macular Degeneration

4951-002 Study – A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients with Neovascular Age-Related Macular Degeneration

ML43000 Belvedere Study – A Phase IV, Open-Label Study of the Response to Treatment after Transition to the Port Delivery System with Ranibizumab (SUSVIMO) in Patients with Neovascular Age-Related Macular Degeneration previously treated with intravitreal agents other than Ranibizumab

OTX-TKI-2023-AMD-303 SOL R Study – A Phase 3, Multicenter, Double-Masked, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (axitinib implant) in Subjects with Neovascular Age-Related Macular Degeneration

VGFTe-HD-OD-2444 Elara Study – A Phase 3B Single Arm Study of Aflibercept 8mg in Participants with Neovascular AMD or Diabetic Macular Edema

EYP-1901-301 Lucia Study– A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD

EYP-1901-302 Lugano Study – A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD

SKG0106-101 Study – A Multicenter, Open-Label, Dose Escalation Phase 1 Clinical Study and Randomized, Double-Masked, Controlled, Dose Expansion Phase 2 Clinical Study to Evaluate the Safety, Preliminary Efficacy, Immunogenicity, and Pharmacokinetics of SKG0106 Intraocular Solution in Patients with Neovascular Age-Related Macular Degeneration

4951-003 Study – A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients with Diabetic Macular Edema

VGFTe-HD-OD-2444 Elara Study – A Phase 3B Single Arm Study of Aflibercept 8mg in Participants with Neovascular AMD or Diabetic Macular Edema

EYE-RES-102 Brunello Study – A Randomized, Double-Masked, 3-Arm Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal EYE103 Compared with Intravitreal Ranibizumab (0.5mg) in Participants with Diabetic Macular Edema

No studies enrolling now

PVT-2201-303 Clarity Study – A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Active, Non-Infectious Intermediate, Posterior, and Panuveitis

81201887NAP0001 Janssen Study – A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants

ANX007-GA-02 Archer 2 Study – A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients with Geographic Atrophy (GA)

SPIAM-301 ReNEW Study – A Phase 3, Randomized, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects who have Dry Age-Related Macular Degeneration

No studies enrolling now